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Abstract
Background—Few population-based studies have evaluated the association between location of 
care, complications with induction therapy and early mortality in acute myeloid leukemia (AML) 
patients.
Methods—Using linked data from the California Cancer Registry and Patient Discharge Dataset 
(1999–2014), we identified adult AML patients (≥18 years) who received inpatient treatment 
within 30 days of diagnosis. A propensity score was created for treatment at an NCI-CC. Inverse 
probability-weighted, multivariable logistic regression models were used to determine associations 
between location of care, complications and early mortality (death ≤ 60 days from diagnosis).
Results—Of the 7007 patients with AML, 1762 (25%) were treated at a NCI-CC. AML patients 
treated at NCI-CCs were more likely to be ≤65 years of age, live in higher socioeconomic status 
neighborhoods, have fewer comorbidities and have public health insurance. Patients treated at 
NCI-CCs had higher rates of renal failure (23% vs 20%, P=0.010) and lower rates of respiratory 
failure (11% vs 14%, P=0.003) and cardiac arrest (1% vs 2%, P=0.014). After adjustment for 
baseline characteristics, treatment at a NCI-CC was associated with lower early mortality (OR 
0.46, CI 0.38–0.57). The impact of complications on early mortality did not differ by location of 
care except for higher early mortality in patients with respiratory failure treated at non-NCI-CC.
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Conclusions—Initial treatment of adult AML at NCI-CCs is associated with a 53% reduction in 
the odds of early mortality compared with treatment at non-NCI-CCs. Lower early mortality may 
result from differences in hospital or provider experience and supportive care.
Condensed abstract:
In this observational cohort study that included 7007 adult acute myeloid leukemia patients 
hospitalized in California, patients treated at National Cancer Institute (NCI) designated cancer 
centers had a 53% reduction in the odds of death at 60 days of diagnosis compared to those treated 
elsewhere. Patients treated at NCI-CCs were more likely to be younger, live in more affluent 
neighborhoods, have fewer comorbidities and have public health insurance.
INTRODUCTION
Acute myeloid leukemia (AML) is the one of the most common leukemias in adults and is 
associated with a poor overall prognosis.1 Initial standard treatment of AML consists of 
induction chemotherapy that usually requires an inpatient hospitalization of at least one 
month, a period that is associated with a high early mortality of 12–26% due to the 
underlying disease and complications of treatment.2–4 Early mortality, or death within 30–60 
days of diagnosis, has improved over the last 40 years largely due to advances in supportive 
care, including treatment of infections and rigorous transfusions5,6, but there continue to be 
disparities in outcomes between specific groups7,8. We previously observed that race/
ethnicity, neighborhood socioeconomic status, marital status and location of care impacted 
early mortality in AML patients.9.
Recent research among patients with solid tumors has highlighted the impact of the cancer 
care delivery setting on patient outcomes. In patients with lung, prostate, breast and 
colorectal cancer, treatment at specialty cancer hospitals compared to community centers 
was associated with improved 1-year mortality after adjustment for cancer stage.10 In 
addition, patients undergoing cancer surgery for lung, gastrointestinal and bladder cancers 
have been shown to experience reduced surgical and late mortality rates when treated at 
National Cancer Institute designated cancer centers (NCI-CC) rather than community 
hospitals.11–13 Few studies have evaluated the association between location of care and 
outcomes in patients with hematological malignancies, including AML. One recent study 
showed that adolescents and young adults with acute lymphoblastic leukemia and acute 
myeloid leukemia treated at NCI-CCs or Children’s Oncology Group sites had better 
survival compared to those treated elsewhere. This study, however, was limited to facilities 
in Los Angeles county and did not consider early mortality.14
In a previous report, we showed that early complications and early mortality were lower for 
AML patients treated at NCI-CC; however, that report did not examine potential reasons for 
this disparity nor utilize more robust analytical methods to mitigate the selection bias 
inherent in which patients receive treatment at an NCI-CC.9 In this present study, we 
examine differences in sociodemographic and clinical characteristics of AML patients 
treated at NCI versus non-NCI-CCs. We also evaluate the impact of hospital type on early 
mortality while controlling for these differences and examine whether complications during 
initial therapy by location of care impact early mortality. We hypothesized that AML 
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patients treated at NCI-CCs would have lower rates of complications related to induction 
therapy and lower early mortality compared to those treated elsewhere.
METHODS
Databases
This study used a linked database between the California Cancer Registry (CCR) and the 
California Office of Statewide Health Planning and Development Patient Discharge 
Database (PDD). The CCR contains sociodemographic, clinical, and pathologic information 
on nearly all patients diagnosed with cancer in California. Reporting is mandatory and 
completeness of cases is at least 98%.15 From the CCR, information on age at diagnosis, 
race/ethnicity, year of diagnosis, gender, marital status, neighborhood socioeconomic status 
(SES), health insurance at diagnosis or initial treatment, date of initial chemotherapy and 
vital status complete through 2014 was obtained.1
The PDD contains information about all patients hospitalized in the California, except 
patients admitted to one of 14 Federal hospitals (12 Veterans Affairs hospitals and two 
military hospitals). Serial records from a single person are linked using an encrypted form of 
the social-security number, called the record linkage number.16,17 PDD records include a 
principal medical diagnosis, up to 24 additional ‘secondary’ diagnoses, and a principal and 
up to 20 secondary procedures coded using International Classification of Diseases, 9th 
Revision, Clinical Modification codes (ICD-9-CM). From the PDD, we obtained 
information on chemotherapy administration, leukapheresis (a procedure used as a surrogate 
for a diagnosis of hyperleukocytosis; ICD-9, 99.72), and comorbidities up to 2 years prior to 
or at AML first admission using the Elixhauser index.18 We were also able to obtain 
information on complications which were included if they occurred within any 
hospitalization from the time of diagnosis to 60 days, or death. Complications determined 
included: major bleeding, sepsis, venous thrombosis, renal failure, liver dysfunction, 
respiratory failure, or cardiac arrest (ICD-9-CM codes in Supplementary Table 1). These 
complications were chosen as they have been previously identified as being common 
complications during AML induction treatment.3 The database also includes a hospital 
identifier. From this list of hospitals, we were able to classify hospitals into those associated 
with one of the eight NCI-CCs in California. All other hospitals were classified as non-NCI-
CCs.
Study Population
Adult patients (≥18 years of age) diagnosed with a first primary AML and treated at a 
hospital with chemotherapy in California from 1999–2014 were eligible for the study. To 
identify cases of AML, we used the following morphology codes from the International 
Classification of Diseases for Oncology, 3rd edition (ICD-O-3) (World Health Organization, 
2000): 9840, 9861, 9865 9867, 9869–9874, 9891, 9895–9898, 9910, 9911, 9920, and 9931. 
We excluded patients with a diagnosis of acute promyelocytic leukemia because the 
treatment and management differs from AML. In addition, we excluded patients without a 
record linkage number to hospital data; patients with an AML diagnosis at autopsy or death 
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certificate only; patients who did not receive chemotherapy within 30 days of diagnosis; and 
those without an inpatient hospitalization or known hospital type (Figure 1).
Statistical Analysis
The differences in baseline characteristics and complications by location of care (NCI-CC vs 
non-NCI-CC facilities) were assessed by Chi-square tests. Propensity score methodology 
was used to balance the baseline covariates between patients treated at an NCI-CC and those 
treated at non-NCI-CC facilities.
Multivariable logistic regression was used to estimate propensity scores for the variable 
location of care (NCI-CC/non-NCI-CC facilities), predicted from baseline characteristics: 
age, sex, race/ethnicity, year of diagnosis, marital status, neighborhood socioeconomic 
status, health insurance type and medical comorbidities. (Supplementary Figure 1). To 
obtain groups similar in baseline characteristics between those treated at NCI and non-NCI 
cancer centers, inverse probability weighting was used in the multivariable models for 
mortality. The quality of the propensity scores estimated are evaluated using two types of 
comparisons: comparing the distributions of propensity scores across the two groups (NCI-
CC/non-NCI-CC facilities) and comparing the distribution of each covariate across the two 
groups. Furthermore, the standardized mean differences in baseline characteristics between 
the NCI-CC and non-NCI-CC groups were used to determine the effectiveness of the 
propensity score adjustment.
The primary outcome was death ≤60 days (early mortality) from AML diagnosis. Inverse 
probability weighted multivariable logistic regression models were used to determine 
associations between location of care and complications with early mortality, adjusting for 
baseline patient characteristics. Interactions of complications and location of care with early 
mortality were also determined for each covariate in the model. Analyses were performed 
using SAS® (9.4) and a two-sided p-value <0.05 was considered statistically significant, 
including interactions.
RESULTS
From a total of 13413 adult patients with first primary AML, we identified 7007 patients that 
fulfilled our inclusion criteria (Figure 1). Of these, 1762 (25.1%) were treated at an NCI-CC. 
The median number of new AML patients per year at a NCI-CC was 13.5 (range 0,43) 
compared to a median of 2 patients per year (range 1, 17) at non-NCI-CCs who admitted at 
least one AML patient. More than half of non-NCI-CCs had a median of zero new AML 
patients per year. By univariate analysis and chi-square tests, patients treated at a NCI-CC 
were more likely to be ≤65 years of age (73.9% vs. 60.1%), live in higher socioeconomic 
status neighborhoods (46.9% vs. 44.1%) and have public insurance (16.9% vs. 11.5%) 
(Table 1). Patients treated at a NCI-CC also had less comorbidities compared to those treated 
elsewhere (79.7% with 0–2 comorbidities at NCI-CC vs. 59.2% with 0–2 comorbidities at 
non-NCI-CC, p<0.001).
In the multivariable model, several sociodemographic and clinical factors were associated 
with treatment at a NCI-CC (Table 2). Age ≤65 years and being diagnosed after 2002 was 
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significantly associated with treatment at a NCI-CC. Having Medicare insurance (OR 1.89, 
CI 1.58–2.24) or other public insurance (OR 1.71, CI 1.44–2.03) was associated with higher 
odds of treatment at a NCI-CC when compared to private insurance. Patients who were 
Hispanic (OR 0.79, CI 0.68–0.92), African American (OR 0.66, CI 0.50–0.87), lived in low 
socioeconomic status neighborhoods (OR 0.84, CI 0.75–0.95) and had more than 3 
comorbidities (0.67, CI 0.57–0.78) were less likely to receive treatment at a NCI-CC.
Differences in complication rates within 60 days of AML diagnosis between NCI-CC and 
non-NCI-CCs are described in Table 3. Leukapheresis occurred more frequently amongst 
patients treated at a NCI-CC (5.5% vs 2.7%, p<0.001). Patients treated at NCI–CCs had 
higher rates of renal failure (22.8% vs 19.9%, p=0.010), but lower rates of respiratory failure 
(11.6% vs 14.3%, p=0.003) and cardiac arrest (1.1% vs 2.0%, p=0.014) than patients treated 
at non-NCI-CCs. At 60 days after diagnosis, more patients treated at NCI-CC were alive 
(88.0% vs 76.3%, p<0.001). Other complications did not significantly differ by location of 
care.
Early mortality amongst AML patients improved over time at both NCI-CCs and non-NCI-
CCs (Figure 2). However, throughout the study period, patients treated at NCI-CCs had a 
persistently lower early mortality (average 12%) relative to those treated at non-NCI-CC 
(average 24%).
After inverse probability weighting and adjustment for sociodemographic factors, 
comorbidities, and complications, treatment at an NCI-CC was associated with significantly 
lower early mortality compared with treatment at a non-NCI-CC (OR 0.46, CI 0.40–0.54) 
(Table 4). Complications associated with increased early mortality included major bleeding, 
liver, renal and respiratory failure, and cardiac arrest. The impact of complications on early 
mortality did not differ by location of care with the exception of respiratory failure (P for 
interaction=0.009) and thrombosis (P for interaction=0.034). AML patients with respiratory 
failure had higher odds of early mortality when treated at non-NCI-CCs (OR 9.48, CI 7.06–
12.74) versus NCI-CCs (OR 4.20, CI 2.61–6.78). Though the association between 
thrombosis and early mortality differed between NCI-CCs and non-NCI-CCs, neither 
association reached statistical significance (Table 4). Similar results were seen in the 
traditional multivariate model (Supplementary Table 2).
DISCUSSION
In our analysis using a large and diverse cohort of hospitalized AML patients receiving 
initial chemotherapy, treatment at NCI–CCs was associated with a 53% reduction in the 
odds of early mortality compared with treatment at non-NCI-CCs. This association persisted 
in propensity-weighted analyses adjusted for sociodemographic factors, comorbidities, and 
complications. We did not find substantial differences in the rates of complications by 
location of care, except that patients treated at NCI-CCs had higher rates of renal failure and 
lower rates of respiratory failure and sepsis. While most complications were associated with 
increased early mortality, patients with respiratory failure had worse outcomes when treated 
at a non-NCI-CC. This study adds to the growing body of research that suggests that access 
to, and type of, hospital may impact cancer outcomes.19,20
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While there have been many successful advances in the care and support of AML patients, 
our findings of such striking variation in early mortality outcomes by cancer care setting 
suggest that these advances may not have disseminated across all treatment settings. This is 
supported by the conclusion of a recent Institute of Medicine report that the cancer care 
system is in crisis with inconsistency in the quality of care being delivered to patients.21 
Further research should evaluate specific differences in the care provided to AML patients 
hospitalized at NCI-CCs compared to other facilities in order to implement policies and 
practices that will ensure that all patients receive high-value and effective care. The NCI 
cancer center designation specifically requires depth and breadth in clinical and basic 
science research and population sciences, cancer prevention programs, and wide-ranging 
clinical resources. Recent research has suggested that the designation may also serve as a 
benchmark to assess the quality of cancer care.10,11,22,23
There are many potential reasons to explain the decreased early mortality seen for patients 
treated at NCI-CCs. It has been reported that high volume centers such as NCI-designated 
cancer centers may have better expertise at performing specialized care than low volume 
non-NCI designated facilities.13,24–26 In this study, NCI-designated cancer centers saw a 
median of 13 AML patients annually while non-NCI cancer centers saw a median of only 2 
patients. A recent study showed reduced inpatient mortality rates in AML patients treated at 
high versus low volume centers.27 High volume centers, defined as those in the highest 
quartile of annual number of AML patients admitted for chemotherapy, had an inpatient 
mortality rate of 1.59% compared to 4.97% in low volume centers (those in the lowest 
quartile). High volume centers may have greater hospital resources, including advanced 
intensive care units, lower nursing staffing ratios and more diagnostic capabilities, factors 
that have been speculated to account for part of the mortality differences seen in surgical 
procedures.28,29 Differences in health care delivery practices between institutions may also 
play a role in outcomes. Prior studies have noted substantial hospital variation in adherence 
to diagnosis, treatment and follow-up guidelines for several malignancies due to both patient 
and hospital specific characteristics including cancer type, availability of multidisciplinary 
consultation, and hospital region.30–33
Because the NCI cancer center designation requires a robust research program, AML 
patients treated at NCI designated cancer centers may have increased access to clinical trials 
with novel agents beyond the standard of care. Prior studies that have evaluated the impact 
of clinical trial enrollment on mortality in cancer found an improvement in lower overall- 
and cancer-specific mortality among common cancer sites.34–36 This access to clinical trials 
may contribute to the improved outcomes seen in AML patients treated at NCI-designated 
cancer centers. This may be especially relevant in AML where molecular discoveries and the 
development of targeted therapies have led to recent approvals of several new drugs based on 
survival improvements demonstrated in clinical trials.37
Patients treated at NCI-CCs had higher rates of renal failure and lower rates of respiratory 
failure and sepsis. Prior studies have noted renal failure as a known complication in acute 
leukemias.38 We speculate that patients at NCI-CCs had higher rates of renal failure due to 
potential administration of nephrotoxic drugs, such as novel agents or antimicrobials. The 
higher rates of leukapheresis we observed at NCI-CCs suggests that patients treated at NCI-
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CCs may have higher white blood cell counts, which is known to be a risk factor for kidney 
dysfunction.39 Renal failure was associated with higher early mortality, but associations did 
not differ by location of care. Patients treated at NCI-CCs who had respiratory failure, 
however, did have lower early mortality than those with respiratory failure treated at non-
NCI-CCs. The higher patient volume at NCI-CCs may result in improved recognition and 
management of common clinical sequelae of AML treatment such as renal and respiratory 
failure.
There are several limitations to our findings. Selection bias was introduced because we 
included only those patients who received chemotherapy and did not include patients who 
received treatment only in the outpatient setting. We did not have information on the specific 
type of chemotherapy given or whether patients were treated on clinical trial protocols at 
NCI-CCs. While this may have contributed to the differences in outcomes seen, we 
speculate that the majority of patients were treated similarly, as induction chemotherapy for 
AML had not significantly changed for the last 40 years despite more recent trends in the 
use of hypomethylating agents for older patients.40 We did not have details on important 
prognostic and predictive factors, including laboratory and molecular data, to consider in our 
early mortality and propensity analyses. As a result, there is likely to be some residual 
confounding from the imbalance in baseline characteristics among patients treated at NCI-
CCs versus non-NCI-CCs. Similar to prior studies41,42, we did observe differences in 
baseline characteristics of patients treated at NCI-CCs: specifically, that they were younger, 
White or Asian race, lived in more affluent neighborhoods and had less comorbidities. 
However, after using propensity score methodology which reduced the standardized mean 
differences to <10% for most variables, the early mortality benefit associated with NCI 
designation persisted. Therefore, it is less likely that the differences in these patient 
characteristics could solely account for the difference noted in outcomes.
Despite these limitations, our study includes a large and diverse patient population with 
findings that are representative of contemporary treatment and health care delivery of AML 
patients at the population-level. The use of these large administrative databases provided the 
statistical power to identify disparities in early mortality that could have implications for 
cancer care and delivery.
In conclusion, this large population-based study in adult hospitalized patients with AML, we 
found a significant reduction in early mortality associated with care at an NCI-designated 
cancer center. This difference persisted even after consideration for differences in rates of 
and outcomes after complications and sociodemographic factors. This finding suggests 
potential disparities in the effectiveness of care for patients with AML across treatment 
facilities, and reinforces the need to further evaluate and measure how care is delivered in 
order to improve outcomes in all care settings.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Analysis cohort of patients with first primary acute myeloid leukemia in California.
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Figure 2. 
60-day Mortality in hospitalized acute myeloid leukemia patients receiving chemotherapy by 
location of care, California, 1999–2014.
*NCI-CC = National Cancer Institute designated cancer center
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Table 1.
Sociodemographic and clinical characteristics of hospitalized acute myeloid leukemia patients receiving 
chemotherapy by location of care, California, 1999–2014.
Total NCI non NCI
N = 7007 N = 1762 N = 5245 P-value*
Age
 18–39 1071 (15.3%) 330 (18.7%) 741 (14.1%)
 40–54 1624 (23.2%) 475 (27.0%) 1149 (21.9%)
 55–65 1761 (25.1%) 497 (28.2%) 1264 (24.1%)
 ≥66 2551 (36.4%) 460 (26.1%) 2091 (39.9%) <.0001
Gender
 Male 3874 (55.3%) 972 (55.2%) 2902 (55.3%)
 Female 3133 (44.7%) 790 (44.8%) 2343 (44.7%) 0.9045
Race/Ethnicity
 White 4292 (61.3%) 1098 (62.3%) 3194 (60.9%)
 African American 366 (5.2%) 71 (4.0%) 295 (5.6%)
 Hispanic 1381 (19.7%) 330 (18.7%) 1051 (20.0%)
 Asian 927 (13.2%) 253 (14.4%) 674 (12.9%)
 Other/unknown 41 (0.6%) 10 (0.6%) 31 (0.6%) 0.0359
Year of diagnosis
 1999–2002 1745 (24.9%) 400 (22.7%) 1345 (25.6%)
 2003–2006 1628 (23.2%) 424 (24.1%) 1204 (23.0%)
 2007–2010 1816 (25.9%) 489 (27.8%) 1327 (25.3%)
 2011–2014 1818 (25.9%) 449 (25.5%) 1369 (26.1%) 0.0361
Marital status at diagnosis
 Married 4182 (59.7%) 1055 (59.9%) 3127 (59.6%)
 Not married 2700 (38.5%) 693 (39.3%) 2007 (38.3%)
 Unknown 125 (1.8%) 14 (0.8%) 111 (2.1%) 0.0098
Neighborhood Socioeconomic status (SES)
 Low SES 3698 (52.8%) 874 (49.6%) 2824 (53.8%)
 High SES 3139 (44.8%) 827 (46.9%) 2312 (44.1%)
 Unknown 170 (2.4%) 61 (3.5%) 109 (2.1%) <.0001
Health insurance status
 Public insurance 902 (12.9%) 298 (16.9%) 604 (11.5%)
 Private insurance 3513 (50.1%) 814 (46.2%) 2699 (51.5%)
 Medicare 2011 (28.7%) 467 (26.5%) 1544 (29.4%)
 Self-pay 116 (1.7%) 35 (2.0%) 81 (1.5%)
 Unknown 465 (6.6%) 148 (8.4%) 317 (6.0%) <.0001
Comorbidities
 0 comorbidities 1419 (20.3%) 408 (23.2%) 1011 (19.3%)
 1–2 comorbidities 2912 (41.6%) 819 (46.5%) 2093 (39.9%)
 3+ comorbidities 2676 (38.2%) 535 (30.4%) 2141 (40.8%) <.0001
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Table 2.
Multivariable model of the relationship of sociodemographic and clinical factors to treatment at a National 
Cancer Institute (NCI)-designated cancer center (versus non-NCI designated cancer center) in hospitalized 
acute myeloid leukemia patients receiving chemotherapy, California 1999–2014.
Variable OR (95% CI) P-value
Age (vs ≥66)
 18–39 2.58 (2.09, 3.20) <.001
 40–54 2.46 (2.03, 2.98) <.001
 55–65 2.29 (1.92, 2.74) <.001
Gender (vs Male)
 Female 0.98 (0.88, 1.10) 0.749
Race/Ethnicity (vs White)
 Asian 0.99 (0.84, 1.17) 0.920
 Hispanic 0.79 (0.68, 0.92) 0.003
 African American 0.66 (0.50, 0.87) 0.004
 Other/unknown 0.92 (0.44, 1.92) 0.819
Year of diagnosis (vs 1999–2002)
 2003–2006 1.19 (1.01, 1.40) 0.034
 2007–2010 1.28 (1.09, 1.50) 0.002
 2011–2014 1.21 (1.03, 1.42) 0.024
Marital status at diagnosis (vs Married)
 Not married 0.99 (0.88, 1.12) 0.876
 Unknown 0.40 (0.23, 0.70) 0.002
Neighborhood Socioeconomic status (vs High)
 Low SES 0.84 (0.75, 0.95) 0.004
 Unknown 1.53 (1.10, 2.14) 0.013
Health insurance status (vs Private insurance)
 Medicare 1.89 (1.58, 2.24) <.001
 Public insurance 1.71 (1.44, 2.03) <.001
 Uninsured 1.49 (0.99, 2.26) 0.057
 Unknown 1.62 (1.31, 2.02) <.001
Comorbidities (vs 0 comorbidities)
 1–2 comorbidities 0.99 (0.86, 1.15) 0.906
 3+ comorbidities 0.67 (0.57, 0.78) <.001
*Adjust for all the variables in the table (age, sex, year of diagnosis, marital status, insurance and comorbidities)
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Table 3.
Complications in hospitalized acute myeloid leukemia patients receiving chemotherapy by location of care, 
California, 1999–2014.
Total NCI-CC non-NCI-CC P-value
N = 7007 N = 1762 N = 5245
Leukapheresis 236 (3.4%) 97 (5.5%) 139 (2.7%) <.001
Sepsis 2,497 (35.6%) 594 (33.7%) 1,903 (36.3%) 0.051
Major bleeding 869 (12.4%) 211 (12.0%) 658 (12.5%) 0.530
Thrombosis 136 (1.9%) 41 (2.3%) 95 (1.8%) 0.175
Renal failure 1,445 (20.6%) 401 (22.8%) 1,044 (19.9%) 0.010
Liver failure 105 (1.5%) 21 (1.2%) 84 (1.6%) 0.221
Respiratory failure 956 (13.6%) 204 (11.6%) 752 (14.3%) 0.004
Cardiac arrest 127 (1.8%) 20 (1.1%) 107 (2.0%) 0.014
Death 1,454 (20.8%) 212 (12.0%) 1,242 (23.7%) <.001
NCI-CC = National Cancer Institute designated cancer center
*Chi-square test
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Table 4.
Inverse probability weighted multivariable model of the relationship of location of care and complications with 
60-day mortality in hospitalized acute myeloid leukemia patients receiving chemotherapy, California 1999–
2014**
Variable OR (95% Cl) P-value
NCI-CC vs non-NCI-CC 0.46 (0.38, 0.57) <.001
Complications
 Major bleeding 1.79(1.39,2.31) <.001
 Sepsis 1.12(0.92, 1.37) 0.263
 Thrombosis* 0.63(0.37, 1.09) 0.100
  NCI-CC 0.12(0.01, 1.07)
  non-NCI-CC 1.06(0.49,2.28)
 Liver failure 1.95(0.96, 3.99) 0.066
 Renal failure 2.33(1.86,2.91) <.001
 Respiratory failure* 6.46(5.01,8.34) <.001
  NCI-CC 4.20(2.61,6.78))
  non-NCI-CC 9.48(7.06, 12.74)
 Cardiac arrest 13.33(5.50,32.32) <.001
Leukapheresis (vs none) 1.51 (0.95,2.39) 0.085
*interaction OR are from stratified models
**
adjusted for age, sex, year of diagnosis, marital status, insurance, comorbidities
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